Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

Review my approach to CAR T-cell therapy—including considerations for patient candidacy and managing toxicities—illustrated with a patient case from my practice.

Stephen J. Schuster, MD Released: October 17, 2019

In this commentary, Matthew J. Frigault, MD, highlights key studies of CAR T-cell therapy that will be presented at the upcoming 2019 ASH annual meeting in Orlando.

Matthew J. Frigault, MD Released: December 4, 2019

Read expert answers to audience questions from a recent symposium on current best practices and emerging directions in CAR T-cell therapy.

Jae H. Park, MD Released: March 24, 2020